Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, April 20, 2025

Systolic blood pressure variability: risk of cardiovascular events, chronic kidney disease, dementia, and death.

Do you really think your competent? doctor will IMMEDIATELY get a testing protocol on this AND a solution protocol to prevent these problems? I doubt it but have your doctor surprise you with competence for once!

 Systolic blood pressure variability: risk of cardiovascular events, chronic kidney disease, dementia, and death.

Xunjie Cheng, Chao Song, Feiyun Ouyang, Tianqi Ma, Lingfang He, Fang FangSee All

BACKGROUND AND AIMS: Earlier studies evaluated the association between systolic blood pressure variability (SBPV) measured during a single period and risk of health outcomes. This study expanded upon existing evidence by examining the association between changes in SBPV over time and clinical outcomes in primary care settings.

METHODS: Visit-to-visit SBPV was determined as standard deviation of ≥3 systolic blood pressure values measured at 5-10 (Period 1) and 0-5 (Period 2) years before enrolment in the UK Biobank. Cox proportional hazards models were used to evaluate associations of absolute changes in SBPV and SBPV change patterns between these two periods with risk of cardiovascular disease (CVD), coronary heart disease (CHD), stroke, atrial fibrillation and flutter (AF), heart failure (HF), chronic kidney disease (CKD), dementia, and overall mortality.

RESULTS: A total of 36 251 participants were included with a median follow-up time of 13.9 years. In the fully adjusted models, an increased SBPV from Period 1 to Period 2 was significantly associated with an increased risk of CVD, CHD, stroke, CKD, and overall mortality (all P for trend < .005), reflecting a 23%-33% increased risk comparing participants with an increase in SBPV above Tertile 3 with those below Tertile 1. An increase in SBPV from Period 1 to Period 2 appeared to be associated with an increased risk of AF, HF, and dementia; however, the associations did not reach statistical significance at P < .005. The restricted cubic spline analysis did not reveal non-linear associations, as all P-values for non-linearity were >.05. Regarding SBPV change patterns, compared with the participants with consistently low SBPV, participants with a consistently high SBPV during the two periods had an increased risk of CVD, CHD, stroke, AF, HF, CKD, and overall mortality, with a risk evaluation of 28%-46%. The observed associations remained largely unchanged across subgroup and sensitivity analyses.

CONCLUSIONS: An increase in SBPV over time was associated with an elevated risk of CVD, CKD, and overall mortality. These findings provide compelling evidence to inform the importance for the management of SBPV in clinical practice.

No comments:

Post a Comment